JP2018508523A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508523A5 JP2018508523A5 JP2017546149A JP2017546149A JP2018508523A5 JP 2018508523 A5 JP2018508523 A5 JP 2018508523A5 JP 2017546149 A JP2017546149 A JP 2017546149A JP 2017546149 A JP2017546149 A JP 2017546149A JP 2018508523 A5 JP2018508523 A5 JP 2018508523A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cochleates
- cocreatate
- tissue
- active substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 22
- 210000001519 tissues Anatomy 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 10
- 229940079593 drugs Drugs 0.000 claims 10
- 239000000126 substance Substances 0.000 claims 10
- 239000002245 particle Substances 0.000 claims 5
- 150000001768 cations Chemical class 0.000 claims 4
- 210000002381 Plasma Anatomy 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 claims 3
- 150000003904 phospholipids Chemical class 0.000 claims 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 229920000023 polynucleotide Polymers 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 210000000577 Adipose Tissue Anatomy 0.000 claims 1
- 210000004100 Adrenal Glands Anatomy 0.000 claims 1
- 210000000988 Bone and Bones Anatomy 0.000 claims 1
- 210000004556 Brain Anatomy 0.000 claims 1
- 210000000845 Cartilage Anatomy 0.000 claims 1
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 claims 1
- 210000000232 Gallbladder Anatomy 0.000 claims 1
- 210000002216 Heart Anatomy 0.000 claims 1
- 210000003016 Hypothalamus Anatomy 0.000 claims 1
- 210000000936 Intestines Anatomy 0.000 claims 1
- 210000003734 Kidney Anatomy 0.000 claims 1
- 101700065453 LAP3 Proteins 0.000 claims 1
- 210000000265 Leukocytes Anatomy 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- 210000004072 Lung Anatomy 0.000 claims 1
- 210000001165 Lymph Nodes Anatomy 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 210000003205 Muscles Anatomy 0.000 claims 1
- 210000001672 Ovary Anatomy 0.000 claims 1
- 210000000496 Pancreas Anatomy 0.000 claims 1
- 229940067631 Phospholipids Drugs 0.000 claims 1
- 230000036823 Plasma Levels Effects 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 210000002307 Prostate Anatomy 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 108020004459 Small Interfering RNA Proteins 0.000 claims 1
- 210000000952 Spleen Anatomy 0.000 claims 1
- 210000003802 Sputum Anatomy 0.000 claims 1
- 210000001179 Synovial Fluid Anatomy 0.000 claims 1
- 210000001550 Testis Anatomy 0.000 claims 1
- 210000001541 Thymus Gland Anatomy 0.000 claims 1
- 210000001685 Thyroid Gland Anatomy 0.000 claims 1
- 210000003932 Urinary Bladder Anatomy 0.000 claims 1
- 210000004291 Uterus Anatomy 0.000 claims 1
- 229940029983 VITAMINS Drugs 0.000 claims 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 claims 1
- 230000000507 anthelmentic Effects 0.000 claims 1
- 230000000844 anti-bacterial Effects 0.000 claims 1
- 230000000843 anti-fungal Effects 0.000 claims 1
- 230000003110 anti-inflammatory Effects 0.000 claims 1
- 230000000842 anti-protozoal Effects 0.000 claims 1
- 230000000692 anti-sense Effects 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003904 antiprotozoal agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 229910052788 barium Inorganic materials 0.000 claims 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium(0) Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims 1
- 239000003781 beta lactamase inhibitor Substances 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- -1 magnesium or barium Chemical class 0.000 claims 1
- 230000001777 nootropic Effects 0.000 claims 1
- 239000002664 nootropic agent Substances 0.000 claims 1
- 230000001817 pituitary Effects 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 229940040975 systemic penicillins Beta-lactamase inhibitors Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960005486 vaccines Drugs 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 229930003231 vitamins Natural products 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
Claims (15)
- コクリエート組成物であって、少なくとも1つの負に帯電したリン脂質と、多価カチオンと、薬理活性物質と、脂質アンカーポリヌクレオチド、脂質アンカー糖、及び脂質アンカーポリペプチドからなる群から選択されるサイズ調整剤とを含む複数のコクリエートを含む、コクリエート組成物。
- 前記複数のコクリエートの平均粒子サイズが10ミクロン未満である、請求項1に記載のコクリエート組成物。
- 前記複数のコクリエートの平均粒子サイズが1ミクロン未満である、請求項2に記載のコクリエート組成物。
- 前記複数のコクリエートの平均粒子サイズが400nm〜800nmである、請求項3に記載のコクリエート組成物。
- 前記複数のコクリエートの平均粒子サイズが、前記サイズ調整剤を用いずに作製したコクリエートの平均粒子サイズの2分の1〜3分の1である、請求項1〜4のいずれか一項に記載のコクリエート組成物。
- 感染組織又は炎症組織を有する哺乳動物への該コクリエート組成物の経口投与が、前記感染組織又は炎症組織において、血漿中の前記薬理活性物質のレベルに比べてより高い該薬理活性物質のレベルをもたらす、請求項1〜5のいずれかに記載のコクリエート組成物。
- 前記コクリエート組成物の経口投与後の前記薬理活性物質の組織内レベルが、該薬理活性物質の血漿中レベルより少なくとも2倍高い、請求項1〜6のいずれかに記載のコクリエート組成物。
- 被験体への前記コクリエート組成物の経口投与の24時間後の感染組織又は炎症組織における前記薬理活性物質の組織内レベルが、健常被験体への経口投与の24時間後の該薬理活性物質の組織内レベルより少なくとも1.5倍高い、請求項1〜7のいずれかに記載のコクリエート組成物。
- 前記組織が腎臓、肺、痰、肝臓、脳、脊椎、髄液、神経、脾臓、心臓、胸腺、リンパ節、動脈壁、膵臓、胆嚢、前立腺、卵巣、子宮、睾丸、甲状腺、副腎、視床下部、脳下垂体、眼、耳、腸、膀胱、筋肉、皮膚、白血球、骨、軟骨、関節組織、滑液及び脂肪組織からなる群から選択される、請求項6〜8のいずれかに記載のコクリエート組成物。
- 前記薬理活性物質が抗真菌薬、β−ラクタマーゼ阻害剤を含むがこれに限定されない抗菌薬、抗ウイルス薬、駆虫薬、抗原虫薬又は抗蠕虫薬、ワクチン、抗炎症剤、siRNA、iRNAを含むがこれらに限定されないポリヌクレオチド、アンチセンス療法又は遺伝子療法用ポリヌクレオチド、免疫療法薬、抗癌剤、抗脂質異常症剤、抗認知症剤、栄養補給剤、ハーブ製品及びビタミンからなる群から選択される、請求項1〜9のいずれかに記載のコクリエート組成物。
- 前記多価カチオンがカルシウム、亜鉛、マグネシウム又はバリウム等の二価金属カチオンである、請求項1〜10のいずれか一項に記載のコクリエート組成物。
- 前記二価金属カチオンがカルシウムである、請求項11に記載のコクリエート組成物。
- 前記少なくとも1つの負に帯電したリン脂質が、前記コクリエート組成物の全リン脂質含量の約20%〜80%、或いは30%〜70%、或いは40%〜60%、或いは45%〜55%の量で存在する、請求項1〜12のいずれか一項に記載のコクリエート組成物。
- 治療を必要とする被験体を治療するための、請求項1〜13のいずれかに記載のコクリエート組成物。
- 感染組織内の薬理活性物質の濃度を血漿中の該薬理活性物質の濃度に比べて増大させるための、請求項1〜13のいずれか一項に記載のコクリエート組成物であり、前記コクリエート組成物の経口投与が、経口投与の24時間後における、血漿中の薬理活性物質の濃度より少なくとも25%高い(1.25倍)、或いは少なくとも50%高い(1.5倍)、或いは少なくとも100%高い(2倍)、或いは少なくとも150%高い、或いは少なくとも200%高い、或いは少なくとも250%高い、或いは少なくとも300%高い、或いは少なくとも350%高い、或いは少なくとも400%高い、或いは少なくとも500%高い、或いは少なくとも600%高い、或いは少なくとも700%高い、或いは少なくとも800%高い、或いは少なくとも1000%高い(11倍)、感染組織内の薬理活性物質の濃度を生じさせる、コクリエート組成物。
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562127799P | 2015-03-03 | 2015-03-03 | |
US62/127,799 | 2015-03-03 | ||
US201562162425P | 2015-05-15 | 2015-05-15 | |
US62/162,425 | 2015-05-15 | ||
US201562163212P | 2015-05-18 | 2015-05-18 | |
US62/163,212 | 2015-05-18 | ||
US201562239675P | 2015-10-09 | 2015-10-09 | |
US62/239,675 | 2015-10-09 | ||
US201562247641P | 2015-10-28 | 2015-10-28 | |
US62/247,641 | 2015-10-28 | ||
US201562264164P | 2015-12-07 | 2015-12-07 | |
US62/264,164 | 2015-12-07 | ||
PCT/US2016/020722 WO2016141203A1 (en) | 2015-03-03 | 2016-03-03 | Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018508523A JP2018508523A (ja) | 2018-03-29 |
JP2018508523A5 true JP2018508523A5 (ja) | 2019-03-28 |
JP6770524B2 JP6770524B2 (ja) | 2020-10-14 |
Family
ID=56848705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017546149A Active JP6770524B2 (ja) | 2015-03-03 | 2016-03-03 | コクリエート、及び薬理活性物質の組織透過性を高めるためにそれを使用する方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US11389407B2 (ja) |
EP (1) | EP3265060B1 (ja) |
JP (1) | JP6770524B2 (ja) |
KR (1) | KR20180004104A (ja) |
CN (1) | CN107847443A (ja) |
AU (1) | AU2016226151B2 (ja) |
CA (1) | CA2978308C (ja) |
WO (1) | WO2016141203A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018337955B2 (en) * | 2017-09-20 | 2024-01-18 | Atopic Medical, Inc. | Compositions and methods for treating and ameliorating respiratory conditions and inflammation of mucosa |
CN107621514B (zh) * | 2017-11-10 | 2020-09-29 | 成都美域高制药有限公司 | 高效液相色谱法测定磷酸特地唑胺对映异构体含量的方法 |
KR101989789B1 (ko) * | 2017-11-30 | 2019-06-18 | (주) 에이치엔에이파마켐 | 포스파티딜세린/음이온계면활성제/염화칼슘을 이용한 코킬레이트 |
WO2019199238A1 (en) * | 2018-04-09 | 2019-10-17 | Vet Products Research And Innovation Center Company Limited | Inorganic mineral entrapped in nanoparticle production method thereof |
BR112022001851A2 (pt) * | 2019-08-13 | 2022-06-21 | Matinas Biopharma Nanotechnologies Inc | Métodos de tratamento de infecções por cryptococcus |
WO2024039733A1 (en) * | 2022-08-16 | 2024-02-22 | Matinas Biopharma Nanotechnologies, Inc. | Methods of controlling lipid nanocrystal particle size and lipid nanocrystals produced by such methods |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4871488A (en) | 1985-04-22 | 1989-10-03 | Albany Medical College Of Union University | Reconstituting viral glycoproteins into large phospholipid vesicles |
US5643574A (en) * | 1993-10-04 | 1997-07-01 | Albany Medical College | Protein- or peptide-cochleate vaccines and methods of immunizing using the same |
US5994318A (en) | 1993-10-04 | 1999-11-30 | Albany Medical College | Cochleate delivery vehicles |
US6153217A (en) | 1999-01-22 | 2000-11-28 | Biodelivery Sciences, Inc. | Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents |
US20030219473A1 (en) * | 2002-03-26 | 2003-11-27 | Leila Zarif | Cochleates made with purified soy phosphatidylserine |
AU2003254598A1 (en) | 2002-08-06 | 2004-02-23 | Tuo Jin | Cochleates without metal cations as the bridging agents |
WO2004064805A1 (en) * | 2003-01-15 | 2004-08-05 | Biodelivery Sciences International, Inc. | Cochleate preparations of fragile nutrients |
US20050013854A1 (en) | 2003-04-09 | 2005-01-20 | Mannino Raphael J. | Novel encochleation methods, cochleates and methods of use |
EP1631669A2 (en) | 2003-04-09 | 2006-03-08 | Biodelivery Sciences International, Inc. | Cochleate compositions directed against expression of proteins |
SG190613A1 (en) * | 2003-07-16 | 2013-06-28 | Protiva Biotherapeutics Inc | Lipid encapsulated interfering rna |
AU2005244262A1 (en) * | 2004-04-09 | 2005-11-24 | Biodelivery Sciences International, Inc. | Nucleotide-cochleate compositions and methods of use |
US20140220108A1 (en) * | 2011-05-05 | 2014-08-07 | University Of Medicine And Dentistry Of New Jersey | Cochleate compositions and methods of making and using same |
WO2013085152A1 (en) * | 2011-12-07 | 2013-06-13 | Union Korea Pharm Co., Ltd. | Combined antibiotics comprising cephalosporins and beta-lactamase inhibitors |
DK2879502T3 (en) | 2012-07-30 | 2018-10-15 | Matinas Biopharma Nanotechnologies Inc | COCHLEATES PREPARED WITH SOYAPHOSPHATIDYLSERINE |
US20180153807A1 (en) | 2015-04-22 | 2018-06-07 | Matinas Biopharma Nanotechnologies, Inc. | Compositions and methods for treating mycobacteria infections and lung disease |
AU2016280276A1 (en) | 2015-06-18 | 2017-12-07 | Matinas Biopharma Nanotechnologies, Inc. | Compositions and methods for treating inflammatory disease or conditions |
-
2016
- 2016-03-03 WO PCT/US2016/020722 patent/WO2016141203A1/en active Application Filing
- 2016-03-03 CN CN201680026006.3A patent/CN107847443A/zh active Pending
- 2016-03-03 AU AU2016226151A patent/AU2016226151B2/en active Active
- 2016-03-03 JP JP2017546149A patent/JP6770524B2/ja active Active
- 2016-03-03 EP EP16759508.1A patent/EP3265060B1/en active Active
- 2016-03-03 KR KR1020177026735A patent/KR20180004104A/ko not_active IP Right Cessation
- 2016-03-03 US US15/554,921 patent/US11389407B2/en active Active
- 2016-03-03 CA CA2978308A patent/CA2978308C/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018508523A5 (ja) | ||
Yang et al. | Synergetic functional nanocomposites enhance immunotherapy in solid tumors by remodeling the immunoenvironment | |
Peng et al. | Local release of TGF‐β inhibitor modulates tumor‐associated neutrophils and enhances pancreatic cancer response to combined irreversible electroporation and immunotherapy | |
Qiu et al. | Celastrol nanoemulsion induces immunogenicity and downregulates PD-L1 to boost abscopal effect in melanoma therapy | |
AU2015254309B2 (en) | Muscle atrophy inhibitor containing quercetin glycoside | |
US11518796B2 (en) | Engineered platelets for targeted delivery of a therapeutic agent | |
Shi et al. | Delivery of MTH1 inhibitor (TH287) and MDR1 siRNA via hyaluronic acid-based mesoporous silica nanoparticles for oral cancers treatment | |
US10646460B2 (en) | Pharmaceutical composition for inhibiting growth of cancer stem cells, containing aldehyde inhibitor and biguanide-based compound | |
Walker et al. | Myeloma bone disease: pathogenesis, current treatments and future targets | |
CN103391768A (zh) | 治疗慢性炎症和炎性疾病的组合物和方法 | |
US11235058B2 (en) | Immunotherapeutic constructs and methods of their use | |
JP2016515533A5 (ja) | ||
WO2021011496A1 (en) | Immunotherapeutic constructs and methods of their use | |
Li et al. | A CD1d-dependent lipid antagonist to NKT cells ameliorates atherosclerosis in ApoE−/− mice by reducing lesion necrosis and inflammation | |
Fang et al. | Atorvastatin suppresses Toll-like receptor 4 expression and NF-κB activation in rabbit atherosclerotic plaques. | |
Hu et al. | Brucine inhibits bone metastasis of breast cancer cells by suppressing Jagged1/Notch1 signaling pathways | |
RU2021135194A (ru) | Способы и аппараты для подготовки клеточных популяций для клеточной терапии | |
Chen et al. | Leukocyte–mimicking Pluronic–lipid nanovesicle hybrids inhibit the growth and metastasis of breast cancer | |
MX2021009082A (es) | Compuestos quimicos. | |
US20180360964A1 (en) | Pharmaceutical composition and a method for producing thereof | |
US20190192555A1 (en) | Compositions comprising nanosilica particles and their use in methods of activating t lymphocytes for therapy | |
Ceccon | Ceritinib as a promising therapy for ALK related diseases | |
Zavoreo et al. | Efficacy of acupuncture and vitamin C in burning mouth syndrome: A pilot study | |
CN114040751A (zh) | 针对微卫星稳定型结直肠癌通过协同性免疫原性细胞死亡促进抗肿瘤响应的槲皮素和土木香内酯的纳米共递送 | |
KR101577271B1 (ko) | 칼슘 이온 및 친수성 비스포스포네이트를 이용한 나노복합체의 제조방법 및 상기 나노복합체를 이용한 약물전달체 |